Summary
Fifteen patients receiving oral melphalan (4.2–5.3 mg/m2) for a variety of neoplastic disorders were studied. Ten patients received the drug on separate occasions, with and without a standardized breakfast. Eight of these patients also received an IV bolus dose (5 mg/m2) to determine bioavailability. Serial melphalan plasma samples were taken over 5 h after administration and assayed by high-performance liquid chromatography. The median area under the curve (AUC) when taken fasting was 179 (range 95–336) ng · h · ml-1, and when taken with food, 122 (47–227) ng · h · ml-1, the median reduction being 39% (P0.01). In one patient, who died before completing the study, the drug was not detectable at all after being taken with food. In the eight patients who were also given IV melphalan, the median terminal melphalan half-life (57 min, range 38–71) was no different from its oral half-life [55 (27–104) min fasting; 55 (30–72) min with food] (P>0.1). In these patients bioavailability was 85% (26–96)% when the drug was taken fasting and 58% (7–99)% when taken with food (P0.025). Median clearance following IV administration was 362 ml/min/m2 (range 104–694). It was found that the melphalan level in a single plasma sample drawn 1.5 h after administration was highly predictive of oral melphalan AUC (rs=0.915, P0.1). This study suggests that to ensure optimum absorption of the drug, melphalan should not be taken with food.
Similar content being viewed by others
References
Alberts DS, Chang SY, Chen H-SG, Evans TL, Moon TE (1979) Oral melphalan kinetics. Clin Pharmacol Ther 26: 737–745
BMDPAR (1979) Derivative-free nonlinear regression. In: Dixon WJ, Brown MB (eds) Biomedical computer programs, P-Series. University of California Press, Los Angeles pp 484–498
Bosanquet AG, Gilby ED (1982) Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18:355–362
Bosanquet AG, Gilby ED (1984) Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma. Cancer Chemother Pharmacol 12:183–186
Gibaldi M, Perrier D (1982) Noncompartmental analysis based on statistical moment theory. In: Swarbrick J (ed) Pharmacokinetics. Dekker, New York (Drugs and the pharmaceutical sciences, vol 15) pp 409–416
Melander A (1978) Influence of food on the bioavailability of drugs. Clin Pharmacokinet 3:337–351
Pinkerton CR, Welshman SG, Glasgow JFT, Bridges JM (1980) Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia? Lancet 2: 944–945
Taha A-K, Ahmad RA, Gray H, Roberts CI, Rogers HJ (1982) Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. Cancer Chemother Pharmacol 9:57–60
Tattersall MHN, Jarman M, Newlands ES, Holyhead L, Milsted RAV, Weinberg A (1978) Pharmacokinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer 14:507–513
Vistica DT (1983) Cellular pharmacokinetics of the phenylalanine mustards. Pharmacol Ther 22:379–405
Woodhouse KW, Hamilton P, Lennard A, Rawlins MD (1983) The pharmacokinetics of melphalan in patients with multiple myeloma: An intravenous/oral study using a conventional dose regimen. Eur J Clin Pharmacol 24:283–285
Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B, Poplack DG (1983) Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukaemia being optimally delivered? N Engl J Med 308:1005–1009
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reece, P.A., Kotasek, D., Morris, R.G. et al. The effect of food on oral melphalan absorption. Cancer Chemother. Pharmacol. 16, 194–197 (1986). https://doi.org/10.1007/BF00256176
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00256176